Clinical Trial Update: Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™ [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating 67Cu-SARTATE for meningioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• 67Cu-SARTATE (Cu-67 labeled SARTATE)

Snippet

Sponsor: Clarity Pharmaceuticals Ltd | Conditions: Meningioma | Phase 1, Phase 2 | Status: COMPLETED